Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)—multicenter real-world analysis from Germany and comparative review of the literature
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06441-8
Abstract: With the introduction of novel agents (proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), immuntherapeutics), the outcome of multiple myeloma (MM) patients has improved. The oral PI ixazomib was authorized in the EU in 11/2016 and is… read more here.
Keywords: rrmm; multiple myeloma; real world; dexamethasone ird ... See more keywords
Real-world analysis of teclistamab in 123 RRMM patients from Germany
Sign Up to like & getrecommendations! Published in 2024 at "Leukemia"
DOI: 10.1038/s41375-024-02154-5
Abstract: Teclistamab, a B-cell maturation antigen (BCMA) × CD3 directed bispecific antibody, has shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with relapsed and refractory multiple myeloma (RRMM). We retrospectively assessed efficacy and… read more here.
Keywords: ide cel; rrmm; world analysis; real world ... See more keywords
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01297-7
Abstract: Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants… read more here.
Keywords: multiple myeloma; rrmm; refractory multiple; relapsed refractory ... See more keywords
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01365-y
Abstract: Dear Editor, Even at the era of T-cell redirecting therapies, patients with relapsed or refractory multiple myeloma (RRMM) presenting extramedullary disease (EMD) and/or high risk cytogenetic abnormalities (HRCA) constitute a particularly challenging sub-group with lower… read more here.
Keywords: prior anti; anti bcma; rrmm; bcma cd3 ... See more keywords
Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2021 at "European journal of haematology"
DOI: 10.1111/ejh.13697
Abstract: BACKGROUND Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple-class relapsed/refractory MM (RRMM). Descriptive analyses were performed on available data for patient characteristics, disease course, and outcomes of… read more here.
Keywords: relapsed refractory; class; triple class; multiple myeloma ... See more keywords
Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134558
Abstract: BACKGROUND Aneuploidy, defined by abnormal copy number changes of chromosomes, contributes to genome instability in multiple myeloma and has potential prognostic impact. Previous research has explored transcriptional pathways affected by aneuploidy. We aim to evaluate… read more here.
Keywords: research; analysis; aneuploidy; research funding ... See more keywords
Novel Therapies for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: A Review of Clinical Trials
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-142903
Abstract: Introduction: Multiple myeloma (MM) is a neoplastic proliferation of plasma cells. It is the second most common hematological malignancy in the US. Although it is associated with poor prognosis, newer therapies have improved outcomes in… read more here.
Keywords: trial; dex; rrmm; efficacy ... See more keywords
Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-193966
Abstract: Background: BCL2 inhibition with venetoclax (Ven) has been shown to benefit patients with relapsed/refractory multiple myeloma (RRMM) harboring t(11;14). Selinexor (X), an XPO1 inhibitor, with dexamethasone (D) is FDA-approved for RRMM. Case reports suggest the… read more here.
Keywords: treatment; rrmm; stage; refractory multiple ... See more keywords
A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-207816
Abstract: Background and Significance: GPRC5D (G Protein-coupled Receptor, Class C, Group 5, Member D) is a known therapeutic target for multiple myeloma (MM). The GPRC5D bispecific T-cell-engager talquetamab was conditionally approved recently by the FDA and… read more here.
Keywords: multiple myeloma; rrmm; adc; study ... See more keywords
MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2274
Abstract: Background: Multiple myeloma (MM) is a highly heterogeneous, incurable hematologic malignancy. BCMA and GPRC5D are highly expressed on MM cells, and targeted therapies such as T-cell engagers (TCEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor… read more here.
Keywords: multiple myeloma; trispecific antibody; rrmm; dose escalation ... See more keywords
Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2631
Abstract: Background Novel immunotherapies such as bispecific antibodies (BsAbs) are rapidly changing the treatment landscape for RRMM, with improved outcomes for patients. As these treatments vary in efficacy, toxicity, dosing, and mode of administration, it is… read more here.
Keywords: treatment; rrmm; response; administration ... See more keywords